Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 249 | 0 | 0 | 570 | 236 |
| Cost of Goods | -714 | 343 | -80 | -222 | 247 |
| Gross Profit | 963 | -343 | 80 | 792 | -11 |
| Operating Expenses | 13,110 | 9,575 | 32,767 | 8,229 | 3,986 |
| Operating Income | -12,861 | -9,575 | -32,767 | -7,659 | -3,750 |
| Interest Expense | -964 | 0 | 0 | 1,864 | 1,553 |
| Other Income | 34,920 | 108,045 | -88,516 | 1,346 | 83 |
| Pre-tax Income | 23,023 | 98,470 | -121,283 | -8,177 | -5,220 |
| Income Tax | -14 | 7 | 7 | -9 | 8 |
| Net Income Continuous | 23,037 | 98,463 | -121,290 | -8,168 | -5,228 |
| Net Income | $23,037 | $98,463 | $-121,290 | $-8,168 | $-5,228 |
| EPS Basic Total Ops | 0.98 | 4.21 | -141.00 | 257.56 | -26.83 |
| EPS Basic Continuous Ops | 4.15 | 95.23 | -141.14 | 258.32 | -26.83 |
| EPS Diluted Total Ops | -2.83 | -14.07 | -141.00 | 257.56 | -26.83 |
| EPS Diluted Continuous Ops | 2.14 | 12.87 | -141.14 | 258.32 | -26.83 |
| EPS Diluted Before Non-Recurring Items | -2.83 | -14.07 | -5.98 | N/A | -26.19 |
| EBITDA(a) | $-12,827 | $-9,542 | $-32,733 | $-3,709 | $-2,580 |